No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: A meta-analysis

Ming Yin; Jingrong Yan; Alexandra Voutsina; Carmelo Tibaldi; David C. Christiani; Rebecca S. Heist; Rafael Rosell; Richard Booton; Qingyi Wei

doi:10.1016/j.lungcan.2010.10.011

No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: A meta-analysis

Ming Yin, Jingrong Yan, Alexandra Voutsina, Carmelo Tibaldi, David C. Christiani, Rebecca S. Heist, Rafael Rosell, Richard Booton, Qingyi Wei

Research output: Contribution to journal › Article › peer-review

Abstract

The nucleotide excision repair (NER) pathway modulates platinum-based chemotherapeutic efficacy by removing drug-induced DNA damage. Methods: To summarize published data on the association between NER genes and responses to platinum-based chemotherapies in non-small cell lung cancer (NSCLC), we performed a meta-analysis of 17 published studies of ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms, including 2097 cancer patients. Primary outcomes included objective response (TR) (i.e., complete response. +. partial response vs. stable disease. +. progressive disease), progression-free survival (PFS) and overall survival (OS). We calculated odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) to estimate the risk or hazard. Results: We found that none of the ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms alone was statistically significantly associated with objective response, PFS and OS in NSCLC patients. Conclusion: There is no evidence to support the use of NER ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms as prognostic predictors of platinum-based chemotherapies in NSCLC. © 2010 Elsevier Ireland Ltd.

Original language	English
Pages (from-to)	370-377
Number of pages	7
Journal	Lung Cancer
Volume	72
Issue number	3
DOIs	https://doi.org/10.1016/j.lungcan.2010.10.011
Publication status	Published - Jun 2011

Keywords

Chemotherapy
DNA repair
Meta-analysis
Pharmacogenetics
Platinum

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lungcan.2010.10.011

Cite this

@article{93511640064f4c2cbd528a60c23a5aac,

title = "No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: A meta-analysis",

abstract = "The nucleotide excision repair (NER) pathway modulates platinum-based chemotherapeutic efficacy by removing drug-induced DNA damage. Methods: To summarize published data on the association between NER genes and responses to platinum-based chemotherapies in non-small cell lung cancer (NSCLC), we performed a meta-analysis of 17 published studies of ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms, including 2097 cancer patients. Primary outcomes included objective response (TR) (i.e., complete response. +. partial response vs. stable disease. +. progressive disease), progression-free survival (PFS) and overall survival (OS). We calculated odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) to estimate the risk or hazard. Results: We found that none of the ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms alone was statistically significantly associated with objective response, PFS and OS in NSCLC patients. Conclusion: There is no evidence to support the use of NER ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms as prognostic predictors of platinum-based chemotherapies in NSCLC. {\textcopyright} 2010 Elsevier Ireland Ltd.",

keywords = "Chemotherapy, DNA repair, Meta-analysis, Pharmacogenetics, Platinum",

author = "Ming Yin and Jingrong Yan and Alexandra Voutsina and Carmelo Tibaldi and Christiani, {David C.} and Heist, {Rebecca S.} and Rafael Rosell and Richard Booton and Qingyi Wei",

year = "2011",

month = jun,

doi = "10.1016/j.lungcan.2010.10.011",

language = "English",

volume = "72",

pages = "370--377",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: A meta-analysis

AU - Yin, Ming

AU - Yan, Jingrong

AU - Voutsina, Alexandra

AU - Tibaldi, Carmelo

AU - Christiani, David C.

AU - Heist, Rebecca S.

AU - Rosell, Rafael

AU - Booton, Richard

AU - Wei, Qingyi

PY - 2011/6

Y1 - 2011/6

N2 - The nucleotide excision repair (NER) pathway modulates platinum-based chemotherapeutic efficacy by removing drug-induced DNA damage. Methods: To summarize published data on the association between NER genes and responses to platinum-based chemotherapies in non-small cell lung cancer (NSCLC), we performed a meta-analysis of 17 published studies of ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms, including 2097 cancer patients. Primary outcomes included objective response (TR) (i.e., complete response. +. partial response vs. stable disease. +. progressive disease), progression-free survival (PFS) and overall survival (OS). We calculated odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) to estimate the risk or hazard. Results: We found that none of the ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms alone was statistically significantly associated with objective response, PFS and OS in NSCLC patients. Conclusion: There is no evidence to support the use of NER ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms as prognostic predictors of platinum-based chemotherapies in NSCLC. © 2010 Elsevier Ireland Ltd.

AB - The nucleotide excision repair (NER) pathway modulates platinum-based chemotherapeutic efficacy by removing drug-induced DNA damage. Methods: To summarize published data on the association between NER genes and responses to platinum-based chemotherapies in non-small cell lung cancer (NSCLC), we performed a meta-analysis of 17 published studies of ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms, including 2097 cancer patients. Primary outcomes included objective response (TR) (i.e., complete response. +. partial response vs. stable disease. +. progressive disease), progression-free survival (PFS) and overall survival (OS). We calculated odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) to estimate the risk or hazard. Results: We found that none of the ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms alone was statistically significantly associated with objective response, PFS and OS in NSCLC patients. Conclusion: There is no evidence to support the use of NER ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms as prognostic predictors of platinum-based chemotherapies in NSCLC. © 2010 Elsevier Ireland Ltd.

KW - Chemotherapy

KW - DNA repair

KW - Meta-analysis

KW - Pharmacogenetics

KW - Platinum

U2 - 10.1016/j.lungcan.2010.10.011

DO - 10.1016/j.lungcan.2010.10.011

M3 - Article

C2 - 21075476

SN - 0169-5002

VL - 72

SP - 370

EP - 377

JO - Lung Cancer

JF - Lung Cancer

IS - 3

ER -

No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: A meta-analysis

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this